Biotech Values

[DewDiligence]

ALQA reverse-merges into (private) Adynxx:

https://www.globenewswire.com/news-release/2019/04/22/1807261/0/en/Adynxx-Announces-Merger-Agreement-with-Alliqua-BioMedical-and-Provides-Business-and-Clinical-Update.html

Adynxx entered into a merger agreement with Alliqua Biomedical, Inc. that will result in Adynxx becoming a Nasdaq-listed public company in early 2019.

Immediately after the merger, the former Adynxx securityholders are expected to own approximately 86% of the combined company, and the existing stockholders of Alliqua are expected to own approximately 14% of the combined company.

Upon closing of the transaction, Alliqua will be renamed Adynxx, Inc. and will be headquartered in San Francisco under the leadership of Adynxx’s current management team. The merger will position Adynxx to rapidly advance its platform of AYX transcription factor decoys and create additional value through pipeline expansion with a strategic focus on pain and inflammatory diseases.